Patient understanding of drug risks: An evaluation of medication guide assessments

Caitlin Knox, Christian Hampp, Mary Willy, Almut G. Winterstein, Gerald Dal Pan

Research output: Contribution to journalArticle

Abstract

Purpose: When a Medication Guide (MG) is part of Risk Evaluation and Mitigation Strategy (REMS), manufacturers assess the effectiveness of MGs through patient surveys, which have not undergone systematic evaluation. We aimed to characterize knowledge rates from these patient surveys, describe their design and respondent characteristics, and explore predictors of acceptable knowledge rates. Methods: We analyzed MG assessments submitted to the Food and Drug Administration from September 2008 through June 2012. We evaluated the prevalence of specific characteristics, and calculated knowledge rates, whereby we defined "acceptable knowledge" when ≥ 80% of respondents correctly answered questions about the primary drug risk. Univariate logistic models were used to investigate the predictors of acceptable knowledge rates. Results: We analyzed the first completed MG assessment for each drug with a patient survey, resulting in 66 unique MG assessments. The mean knowledge rate was 63.8%, with 20 MG assessments (30.3%) achieving the 80% threshold. Compared to assessments that did not reach acceptable knowledge rates, those that did were more likely associated with additional REMS elements (e.g. Elements to Assure Safe Use or Communication Plans). Other factors, including mean age, reading or understanding the MG, and being offered or accepting counseling were not associated with knowledge rates. There was considerable variation in the design of MG assessments. Conclusions: Most MG assessments did not reach the 80% knowledge threshold, but those associated with additional interventions were more likely to achieve it. Our study highlights the need to improve patient-directed information and the methods of assessing it.

Original languageEnglish (US)
Pages (from-to)518-525
Number of pages8
JournalPharmacoepidemiology and Drug Safety
Volume24
Issue number5
DOIs
StatePublished - May 1 2015
Externally publishedYes

Fingerprint

Pharmaceutical Preparations
United States Food and Drug Administration
Counseling
Reading
Logistic Models
Communication
Surveys and Questionnaires

Keywords

  • FDA
  • Knowledge
  • Medication guide
  • Pharmacoepidemiology
  • REMS

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Epidemiology

Cite this

Patient understanding of drug risks : An evaluation of medication guide assessments. / Knox, Caitlin; Hampp, Christian; Willy, Mary; Winterstein, Almut G.; Pan, Gerald Dal.

In: Pharmacoepidemiology and Drug Safety, Vol. 24, No. 5, 01.05.2015, p. 518-525.

Research output: Contribution to journalArticle

Knox, Caitlin ; Hampp, Christian ; Willy, Mary ; Winterstein, Almut G. ; Pan, Gerald Dal. / Patient understanding of drug risks : An evaluation of medication guide assessments. In: Pharmacoepidemiology and Drug Safety. 2015 ; Vol. 24, No. 5. pp. 518-525.
@article{fc49504894004f57bdf3e58c24b2cb67,
title = "Patient understanding of drug risks: An evaluation of medication guide assessments",
abstract = "Purpose: When a Medication Guide (MG) is part of Risk Evaluation and Mitigation Strategy (REMS), manufacturers assess the effectiveness of MGs through patient surveys, which have not undergone systematic evaluation. We aimed to characterize knowledge rates from these patient surveys, describe their design and respondent characteristics, and explore predictors of acceptable knowledge rates. Methods: We analyzed MG assessments submitted to the Food and Drug Administration from September 2008 through June 2012. We evaluated the prevalence of specific characteristics, and calculated knowledge rates, whereby we defined {"}acceptable knowledge{"} when ≥ 80{\%} of respondents correctly answered questions about the primary drug risk. Univariate logistic models were used to investigate the predictors of acceptable knowledge rates. Results: We analyzed the first completed MG assessment for each drug with a patient survey, resulting in 66 unique MG assessments. The mean knowledge rate was 63.8{\%}, with 20 MG assessments (30.3{\%}) achieving the 80{\%} threshold. Compared to assessments that did not reach acceptable knowledge rates, those that did were more likely associated with additional REMS elements (e.g. Elements to Assure Safe Use or Communication Plans). Other factors, including mean age, reading or understanding the MG, and being offered or accepting counseling were not associated with knowledge rates. There was considerable variation in the design of MG assessments. Conclusions: Most MG assessments did not reach the 80{\%} knowledge threshold, but those associated with additional interventions were more likely to achieve it. Our study highlights the need to improve patient-directed information and the methods of assessing it.",
keywords = "FDA, Knowledge, Medication guide, Pharmacoepidemiology, REMS",
author = "Caitlin Knox and Christian Hampp and Mary Willy and Winterstein, {Almut G.} and Pan, {Gerald Dal}",
year = "2015",
month = "5",
day = "1",
doi = "10.1002/pds.3762",
language = "English (US)",
volume = "24",
pages = "518--525",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Patient understanding of drug risks

T2 - An evaluation of medication guide assessments

AU - Knox, Caitlin

AU - Hampp, Christian

AU - Willy, Mary

AU - Winterstein, Almut G.

AU - Pan, Gerald Dal

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Purpose: When a Medication Guide (MG) is part of Risk Evaluation and Mitigation Strategy (REMS), manufacturers assess the effectiveness of MGs through patient surveys, which have not undergone systematic evaluation. We aimed to characterize knowledge rates from these patient surveys, describe their design and respondent characteristics, and explore predictors of acceptable knowledge rates. Methods: We analyzed MG assessments submitted to the Food and Drug Administration from September 2008 through June 2012. We evaluated the prevalence of specific characteristics, and calculated knowledge rates, whereby we defined "acceptable knowledge" when ≥ 80% of respondents correctly answered questions about the primary drug risk. Univariate logistic models were used to investigate the predictors of acceptable knowledge rates. Results: We analyzed the first completed MG assessment for each drug with a patient survey, resulting in 66 unique MG assessments. The mean knowledge rate was 63.8%, with 20 MG assessments (30.3%) achieving the 80% threshold. Compared to assessments that did not reach acceptable knowledge rates, those that did were more likely associated with additional REMS elements (e.g. Elements to Assure Safe Use or Communication Plans). Other factors, including mean age, reading or understanding the MG, and being offered or accepting counseling were not associated with knowledge rates. There was considerable variation in the design of MG assessments. Conclusions: Most MG assessments did not reach the 80% knowledge threshold, but those associated with additional interventions were more likely to achieve it. Our study highlights the need to improve patient-directed information and the methods of assessing it.

AB - Purpose: When a Medication Guide (MG) is part of Risk Evaluation and Mitigation Strategy (REMS), manufacturers assess the effectiveness of MGs through patient surveys, which have not undergone systematic evaluation. We aimed to characterize knowledge rates from these patient surveys, describe their design and respondent characteristics, and explore predictors of acceptable knowledge rates. Methods: We analyzed MG assessments submitted to the Food and Drug Administration from September 2008 through June 2012. We evaluated the prevalence of specific characteristics, and calculated knowledge rates, whereby we defined "acceptable knowledge" when ≥ 80% of respondents correctly answered questions about the primary drug risk. Univariate logistic models were used to investigate the predictors of acceptable knowledge rates. Results: We analyzed the first completed MG assessment for each drug with a patient survey, resulting in 66 unique MG assessments. The mean knowledge rate was 63.8%, with 20 MG assessments (30.3%) achieving the 80% threshold. Compared to assessments that did not reach acceptable knowledge rates, those that did were more likely associated with additional REMS elements (e.g. Elements to Assure Safe Use or Communication Plans). Other factors, including mean age, reading or understanding the MG, and being offered or accepting counseling were not associated with knowledge rates. There was considerable variation in the design of MG assessments. Conclusions: Most MG assessments did not reach the 80% knowledge threshold, but those associated with additional interventions were more likely to achieve it. Our study highlights the need to improve patient-directed information and the methods of assessing it.

KW - FDA

KW - Knowledge

KW - Medication guide

KW - Pharmacoepidemiology

KW - REMS

UR - http://www.scopus.com/inward/record.url?scp=84928193313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928193313&partnerID=8YFLogxK

U2 - 10.1002/pds.3762

DO - 10.1002/pds.3762

M3 - Article

C2 - 25808393

AN - SCOPUS:84928193313

VL - 24

SP - 518

EP - 525

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 5

ER -